We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Pharmacodynamics: the drug in the body
- DNA synthesis inhibitors (1)
- DNA synthesis inhibitors (2)
- Antimetabolites
- Antimetabolites: folate antagonists
- DNA damaging agents
- DNA synthesis inhibitors (3)
- Microtubule targeting agents
- Monoclonal antibodies
- The Philadelphia chromosome
- Cytogenetic abnormality of CML (Phil. chrom.)
- Targeted therapies bind in specific locations
- Targeted agents
- Drug receptor interactions: EGFR signaling
- EGFR mutations
- Dose-response relationships
- Exposure-response relationships
- Examples of dose response relationship
- Talk summary
Topics Covered
- Principles of pharmacodynamics
- Mechanisms of action of anticancer agents
- Evolution from non-specific DNA damagers to targeted therapies
- Integrated pharmacokinetics, dynamics and genomics dose response model
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Kolesar, J. (2017, May 29). Overview of clinical pharmacology in cancer 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 7, 2024, from https://doi.org/10.69645/HOEG1124.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Jill Kolesar has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Overview of clinical pharmacology in cancer 2
Published on May 29, 2017
17 min
Other Talks in the Series: Cancer Therapies in the Personalized Medicine Era
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. I'm Jill Kolesar.
Today we're going to talk about the second part of the lecture,
which is the pharmacodynamics of anticancer agents.
0:09
So, let's move on to pharmacodynamics,
which is what the drug does to the body.
So, in pharmacodynamics we draw a different type of
curve and this is concentration versus effect curve.
So, in this diagram,
you can see concentration is going to be on the x-axis,
so that's concentration in plasma,
and then we look at effect and that's going to be on the y-axis.
So, what you can see from this slide that way to the very left of the diagram,
where the concentration is low,
you'll have little effect,
and then what we like to see with drugs,
so this is kind of an ideal concentration versus
effect slide that we have a linear relationship between concentration effect.
So, you can see that in a more linear part of the curve and then typically,
you reach a plateau effect where even as concentration goes higher,
you don't get a higher effect.
So, this is a typical diagram for drug-receptor interactions.
Drugs typically act by binding to receptors and they may activate or inactivate it.
It's also a mechanism of action for anticancer agents.
What we're really looking for here is our dose response relationships.
1:16
So, let's look at some of our anticancer drugs and how they work.
So, the mechanism of action,
one of the main things we have are DNA synthesis inhibitors.
So, we have purines which are the adenine and guanine and
we have pyrimidines which are the cytosines and thymines.
So, in the Purine family we have Pentostatin which inhibits adenosine deaminase,
6-MP, which inhibits purine ring biosynthesis
and methotrexate which inhibits purine ring biosynthesis as well.
So, essentially what these drugs are doing,
is they're preventing the synthesis of the building blocks of DNA,
so therefore, the DNA cannot be synthesized because you run out of starting materials.